The scrutiny centers on an August 13, 2026, financial update. While Abeona reported that five patients received treatment with its one-time therapy, prademagene zamikeracel, the company acknowledged that revenue could only be recognized for four of those cases. Management attributed the shortfall to a specific batch of the product that failed to meet the required sheet count for financial recognition.
Pomerantz LLP Launches Investigation Into Abeona Therapeutics
A 15% slide in Abeona Therapeutics stock has triggered a formal investigation by the New York-based Pomerantz LLP. The firm is currently probing whether the company or its leadership committed securities fraud following disclosures regarding revenue recognition issues related to its therapy, ZEVASKYN.
Following the announcement, shares of the NASDAQ-listed company dropped by $1.12, closing at $6.35. Pomerantz LLP, a firm with a long-standing history in corporate and securities litigation, is now inviting investors to come forward as they evaluate potential breaches of fiduciary duty or unlawful business practices. Investors seeking to participate in the ongoing review are directed to contact Danielle Peyton for further legal guidance.
Comments (0)
No comments yet. Be the first!